Rotavirus vaccine RIX4414 (Rotarix™): A review of its use in the prevention of rotavirus gastroenteritis

Pediatric Drugs

Volumn 11, Issue 1, 2009, Pages 75-88

  McCormack, Paul L ^a,b   Keam, Susan J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug evaluations; Gastroenteritis; Rotavirus vaccine, therapeutic use

Indexed keywords

ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE;

ANOREXIA; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEVER; GASTROENTERITIS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INTUSSUSCEPTION; IRRITABILITY; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RHINORRHEA; ROTAVIRUS; SEROCONVERSION; SIDE EFFECT; VIRUS SHEDDING; VOMITING;

ADMINISTRATION, ORAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GASTROENTERITIS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 58149328772     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/0148581-200911010-00025     Document Type: Conference Paper

References (55)

1. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006 Aug 11; 55 (RR-12): 1-13
2. Parashar UD, Gibson CJ, Bresee JS, et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006 Feb; 12 (2): 304-6
3. Rotavirus vaccines: WHO position paper. Wkly Epidemiol Rec 2007 Aug 10; 82 (32): 285-95
4. Soriano-Gabarro M, Mrukowicz J, Vesikari T, et al. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006 Jan; 25 Suppl. 1: S7-11
5. Cunliffe N, Nakagomi O. Introduction of rotavirus vaccines in developing countries: remaining challenges. Ann Trop Paediatr 2007 Sep; 27 (3): 157-67
6. Khamrin P, Maneekarn N, Peerakome S, et al. Novel porcine rotavirus of genotype P[27] shares new phylogenetic lineage with G2 porcine rotavirus strain. Virology 2007 May 10; 361 (2): 243-52
7. Grimwood K, Bines JE. Rotavirus vaccines must perform in low-income countries too. Lancet 2007 Nov 24; 370 (9601): 1739-40
8. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005 Jan-2005 28; 15 (1): 29-56
9. Glass RI, Bresee JS, Parashar UD, et al. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 2004 May 8; 363 (9420): 1547-50
10. Nakagomi O, Cunliffe NA. Rotavirus vaccines: entering a new stage of deployment. Curr Opin Infect Dis 2007 Oct; 20 (5): 501-7
11. Simonsen L, Viboud C, Elixhauser A. More on Rotashield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005 Sep; 192 Suppl. 1: S36-43
12. European Medicines Agency. Rotarix: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2008 Jun 24]
13. US FDA. Rotarix® (rotavirus vaccine, live, oral): US prescribing information [online]. Available from URL: http://www.fda.gov/CBER/label/ rotarixLB.pdf [Accessed 2008 Jun 24]
14. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998 Feb; 16 (4): 381-7
15. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004 Jul 29; 22: 2836-42
16. Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 2005 Jun; 24 (6): 481-8
17. Phua KB, Quak SH, Lee BW, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis 2005 Sep 1; 192 Suppl. 1: S6-16
18. Salinas B, Schael IP, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebocontrolled trial in Latin American infants. Pediatr Infect Dis J 2005 Sep; 24 (9): 807-16
19. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004 Oct; 23 (10): 937-43
20. Vesikari T, Prymula R, Schuster V, et al. Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphtheria-tetanus-pertussis (DTPa)-combined vaccines in healthy infants from Europe [abstract]. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2006 May 3-5; Basel
21. Vesikari T, Karvonen A, Prymula R, et al. Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries [abstract]. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2006 May 3-5; Basel
22. Zibrik L, Dove W, McArdle F, et al. Lack of shedding of the RIX4414 live attenuated rotavirus vaccine administered to adult volunteers. Arch Virol 2007; 152 (10): 1951-4
23. Dennehy PH, Bertrand HR, Silas PE, et al. Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States. Pediatrics 2008 Nov; 122 (5): e1062-6
24. Steele AD, De Vos B, Tumbo J, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine. Epub 2008 Sep 9
25. Lopez P, Abate HJ, De Leon T, et al. Immunogenicity of an oral polio vaccine is unaffected when co-administered with a human vaccine RIX4414 (Rotarix™) in Latin America [abstract no. 19.029]. 13th International Congress on Infectious Diseases; 2008 Jun 19-22; Kuala Lumpur
26. Tregnaghi M, Lopez P, De Leon T, et al. Oral human rotavirus vaccine RIX4414 (Rotarix™) co-administered with routine EPI vaccinations including oral poliovirus vaccine (OPV) is highly efficacious in Latin-America [abstract no. 19.020]. 13th International Congress on Infectious Diseases; 2008 Jun 19-22; Kuala Lumpur
27. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007 Nov 24; 370 (9601): 1757-63
28. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006 Jan 5; 354 (1): 11-22
29. Linhares AC, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008 Apr 5; 371 (9619): 1181-9
30. Phua KB, Lim FS, Lau YL, et al. Human rotavirus vaccine RIX4414 (Rotarix™) is highly efficacious in infants from Asia during the first two years of life [abstract no. 19.024]. 13th International Congress on Infectious Diseases; 2008 Jun 19-22; Kuala Lumpur
31. Madhi S, Lerumo T, Louw C, et al. Efficacy of human rotavirus vaccine RIX4414 (Rotarix™) in South African infants during the first year of life: an interim report [abstract]. 8th International Rotavirus Symposium; 2008 Jun 3-4; Istanbul
32. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22 (3): 259-67
33. Vesikari T, Prymula R, Schuster V, et al. Early protection against rotavirus, Rotarix™ (RIX4414) experience in a European setting [abstract no. 68.021]. Int J Infect Dis 2006 Jun; 10 Suppl. 1: 324
34. Perez-Schael I, Salinas B, Tomat M, et al. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. J Infect Dis 2007 Aug 15; 196 (4): 537-40
35. Araujo EC, Clemens SA, Oliveira CS, et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy Brazilian infants. J Pediatr (Rio J) 2007 May 30; 83 (3): 217-24
36. Linhares AC, Verstraeten T, Wolleswinkel-van den Bosch J, et al. Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clin Infect Dis 2006 Aug 1; 43 (3): 312-4
37. de Soarez PC, Valentim J, Sartori AM, et al. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008 Apr; 23 (4): 221-30
38. Goossens LM, Standaert B, Hartwig N, et al. The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands. Vaccine 2008 Feb 20; 26 (8): 1118-27
39. Isakbaeva ET, Musabaev E, Antil L, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007 Jan 4; 25 (2): 373-80
40. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II: the potential cost-effectiveness of vaccination. Vaccine 2007 May 16; 25 (20): 3971-9
41. Lorgelly PK, Joshi D, Iturriza Gomara M, et al. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008 Jan; 136 (1): 44-55
42. Melliez H, Levybruhl D, Boelle PY, et al. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008 Jan 30; 26 (5): 706-15
43. Newall AT, Beutels P, Macartney K, et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007 Dec 17; 25 (52): 8851-60
44. Standaert B, Marocco A, Assael B, et al. Cost-effectiveness of universal rotavirus vaccination with Rix4414 in Italy [in Italian]. Pharmacoeconomics - Italian Research Articles 2008 Jan; 10 (1): 23-35
45. Fruytier A, Van Schoor J, Standaert B. Vaccination with RIX4414 is cost-effective in a Belgian setting [abstract no. PIH3]. Value Health 2006 Nov; 9 (6): A253. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research 9th Annual European Congress; 2006 Oct 28-31; Copenhagen
46. Hammerschmidt T, Forster J, Huppertz HI, et al. Epidemiologic and economic impact of routine vaccination of infants against rotavirus gastroenteritis in Germany: a preliminary analysis [abstract no. PIN6]. Value Health 2007 Nov 31; 10 (6): A437
47. Standaert B, Harlin O, Desselberger U. The financial burden of rotavirus disease in four countries of the European Union. Pediatr Infect Dis J 2008 Jan; 27 Suppl. 1: S20-7
48. De Vos B, Vesikari T, Linhares AC, et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 2004 Oct; 23 Suppl. 10: S179-82
49. RotaTeq (rotavirus vaccine, live, oral, pentavalent): US prescribing information. Whitehouse Station (NJ): Merck & Co., Inc., 2008 Apr
50. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008 May; 46 Suppl. 2: S38-48
51. Advisory Committee on Immunization Practices. ACIP provisional recommendations for the prevention of rotavirus gastroenteritis among infants and children [online]. Available from URL: http://www.cdc.gov/vaccines/recs/ provisional/downloads/roto-7-1-08-508.pdf [Accessed 2008 Jul 25]
52. Meyer N, Diez-Domingo J, Baldo JM, et al. Primary care-based surveillance to estimate the burden of rotavirus gastroenteritis in children aged <5 years in Europe [abstract]. 26th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2008 May 13-17; Graz
53. Grimwood K, Buttery JP. Clinical update: rotavirus gastroenteritis and its prevention. Lancet 2007 Jul 28; 370 (9584): 302-4
54. Soriano-Gabarro M, Verstraeten T, Gillard P, et al. Potential impact of Rotarix according to rotavirus type distribution. Pediatr Infect Dis J 2008 Jan; 27 Suppl. 1: S28-32
55. Nelson EAS, Bresee JS, Parashar UD, et al. Rotavirus epidemiology: the Asian Rotavirus Surveillance Network. Vaccine 2008 Jun 19; 26 (26): 3192-6